Teva Recalls Eptifibatide Injection Vials Due to Manufacturing Deviations
Teva North America is voluntarily recalling 14,661 vials of Eptifibatide Injection due to CGMP deviations. The recall covers lots distributed nationwide and in Puerto Rico.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a reasonable probability of temporary or medically reversible health consequences. The source cites CGMP deviations without reporting specific illnesses or injuries, aligning with a moderate severity rating for a voluntary precautionary recall.
Plain-English summary
Teva North America is voluntarily recalling 14,661 vials of Eptifibatide Injection 75 mg/100 mL (0.75 mg/mL) single-use vials. The product is manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC. The recall was initiated on June 17, 2016, and was classified as Class II by the FDA.
The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations. The affected lots are 2710715, 2720715, 2730715, 3110715, and 3120715. These products were distributed nationwide and in Puerto Rico.
The recall was terminated on February 7, 2017. Patients and healthcare providers should check their inventory for the specific lot numbers listed and contact Teva North America or the FDA for further instructions.
The recalled product
- Product
- Eptifibatide Injection 75 mg/100 mL (0.75 mg/mL) single use vial, For Intravenous Use Only, Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC# 0703-1179-01.
- Manufacturer
- Teva North America
- Category
- Drug — Injection
- Hazard
- Affected units
- 14,661
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- All Lots Within Expiry Lot# 2710715
- 2720715
- 2730715
- 3110715
- 3120715
Distribution
Part of a larger recall action
This product is one of 4 recalled by Teva North America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Teva North America
See all →- ModerateTeva Recalls Claravis Isotretinoin Capsules Due to Impurity Failures
FDA (Drugs) · 2016-10-12
- ModerateTeva Recalls Ondansetron Injection Vials Due to Manufacturing Deviations
FDA (Drugs) · 2016-09-14
- ModerateTeva Recalls Argatroban Injection Due to Manufacturing Deviations
FDA (Drugs) · 2016-09-14
- SevereTeva Recalls Linezolid Injection Due to Manufacturing Deviations
FDA (Drugs) · 2016-09-14
- ModerateTeva Recalls Amoxicillin Oral Suspension Due to Potency Issues
FDA (Drugs) · 2016-08-31
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19